Pacific Biosciences' Q4'24 results were another disappointment, with revenue and margin misses, and 2025 guidance was notably below expectations. Underlying utilization growth (genetic data ...

MENLO PARK, CA – Pacific Biosciences of California, Inc. (NASDAQ:PACB), a leader in laboratory analytical instruments with a market capitalization of $357.59 million, has entered into a ...

MENLO PARK, CA – Pacific Biosciences of California, Inc. (NASDAQ:PACB), a leader in laboratory analytical instruments with a market capitalization of $357.59 million, has entered into a significant ...

Pacific Biosciences of California, Inc. has a 52-week low of $1.16 and a 52-week high of $5.01. The company has a market cap of $366.98 million, a price-to-earnings ratio of -0.82 and a beta of 1.92.

In the last three months, 4 analysts have published ratings on Pacific Biosciences PACB, offering a diverse range of perspectives from bullish to bearish. In the table below, you'll find a summary ...

Pacific Biosciences of California has a 12-month low of $1.16 and a 12-month high of $6.09. The company has a quick ratio of 8.64, a current ratio of 9.74 and a debt-to-equity ratio of 1.97.

CHARLESTOWN, Mass., March 06, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing ...

Adverse events were mostly mild to moderate in severity and consistent with those typically observed in AAV gene therapy. SLDB plans to request an FDA meeting in mid-2025 to discuss a potential ...